Israel Medica2010 Companies Catalogue - Israeli-South African ...

Flexicath
Back to TOC
www.flexicath.com
Company at a Glance
Flexicath developed and market breakthrough catheter insertion systems to ensure simple, safe, and sterile
intravenous catheterization.
Addressing the need for a safe, easy-to-insert catheter for up to a 29-day treatment period, Flexicath has
developed the M/29, a technology that combines a 30-day indweller IV catheter with special designed OTN
introducers and an innovative 360 maximum barrier self-enclosed design to allow completely sterile
insertion systems that are:
• Safer and reduce risk of contact or airborne infections
• Easier to use
• More cost-effective, and do not require an external sterile environment
Category, Subcategory & Therapeutic Area(s)
Category:
Subcategory:
Therapeutic Area(s):
Company Status:
Medical Devices
Disposable, Implantable
Hematology, Intensive Care, Internal Medicine, Oncology, Orthopedic, Pediatrics,
Peripheral Vascular
Initial Revenues
Technology & Product(s)
The M/29 combines a standard PICC line-type catheter that is completely enclosed in a sterile silicon sleeve
and PeelGuard, a special silicone insertion unit. The sleeve creates a self-contained, sterile insertion field
to form a 3D 360 maximum barrier.
This design has several advantages:
• Throughout the insertion procedure the catheter is fully encased and prevents touch and airborne
contamination.
• The system virtually eliminates blood backflow.
• The insertion procedure is safe, simple, can be done by a floor nurse and is cost effective.
• The M/29 has IV dwell time of up to 29 days
Goal
Objectives:
Target Businesses:
Target Countries:
Distribution, Alliances
Industry leaders, manufacturers
Germany, France, UK, Italy, Spain, South Africa, Australia
26